Novartis jumps as Q1 update reassures on guidance and accelerating key-drug growth
Novartis shares rose about 3% as investors digested the company’s Q1 2026 update that reaffirmed full-year guidance and highlighted strong growth in priority brands like Kisqali. The move also reflects continued capital returns, including $1.6 billion of Q1 share repurchases under its $10 billion buyback program.
1) What’s driving the move
Novartis (NVS) is trading higher as the market refocuses on its latest Q1 2026 results package and outlook commentary, which reaffirmed full-year 2026 guidance while pointing to strong momentum in priority brands and launches. The company also reiterated ongoing shareholder returns, including active repurchases under its multi-billion-dollar buyback authorization, which can provide incremental demand for shares and support sentiment. (novartis.com)
2) The key numbers investors are reacting to
In its Q1 2026 reporting, Novartis posted net income of about $3.16 billion and adjusted earnings of $1.99 per share, alongside commentary that generic erosion in the U.S. weighed on results as expected. However, product-level strength stood out—Kisqali sales were highlighted as sharply higher year over year—helping investors look through near-term headwinds and toward durability of the growth portfolio. (wtop.com)
3) Guidance, buybacks, and what’s next
Novartis reaffirmed its FY 2026 framework (low single-digit net sales growth and a low single-digit decline in core operating income), a key stabilizer for expectations amid broader sector concerns around pricing and patent cliffs. The company also disclosed Q1 repurchases of roughly 10.4 million shares for $1.6 billion under its up-to-$10 billion share buyback program (with a large remaining authorization), which can amplify upside on days when uncertainty fades and investors re-risk into defensives. (novartis.com)